Dosing regimens for treatment of proliferative disorders comprising administration of sapacitabine

A method of treating a proliferative disorder selected from the group consisting of acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), non small cell lung cancer (NSCLC), cutaneous T-cell lymphoma (CTCL), Mycosis fungoides (MF) and Sezary syndrome (SS) comprising administering a therapeutically effective amount of sapacitabine, or a metabolite thereof which is 2′-C-Cyano-2′-deoxy-β-D-arabinopentafuranosylcytosine (CNDAC), to a human subject in need thereof in accordance with a dosing regimen comprising at least one treatment cycle, wherein said treatment cycle for the sapacitabine or the metabolites thereof consists of:

• (i) administering therapeutically effective amount of sapacitabine or the metabolite thereof for 5 consecutive days per week, for 2 weeks, wherein the sapacitabine or metabolite thereof is administered in a total daily dosage of from about 125 to about 375 mg, followed by;
• (ii) a rest period of 1 week during which no sapacitabine or metabolite thereof is administered.